{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:31:05Z","timestamp":1697391065002},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s11938-006-0042-3","type":"journal-article","created":{"date-parts":[[2007,6,18]],"date-time":"2007-06-18T15:54:18Z","timestamp":1182182058000},"page":"234-245","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of refractory ulcerative colitis"],"prefix":"10.1007","volume":"9","author":[{"given":"Sunana","family":"Sohi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"42_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/01.MIB.0000161308.65951.db","volume":"11","author":"A Yang","year":"2005","unstructured":"Yang A, Chen Y, Scherl E, et al.: Inflammatory bowel disease in patients with celiac disease. Inflamm Bowel Dis 2005, 11:528\u2013532.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004836-199707000-00007","volume":"25","author":"S Ardizzone","year":"1997","unstructured":"Ardizzone S, Molteni P, Imbesi V, et al.: Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997, 25:330\u2013333.","journal-title":"J Clin Gastroenterol"},{"key":"42_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485\u2013489. Although a retrospective review, this is one of the largest, most comprehensive studies establishing a role for the purine analogues in the induction and maintenance of remission in IBD patients.","journal-title":"Gut"},{"key":"42_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00004836-200309000-00006","volume":"37","author":"JI Warman","year":"2003","unstructured":"Warman JI, Korelitz BI, Fleisher MR, Janardhanam R: Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn\u2019s disease and ulcerative colitis. J Clin Gastroenterol 2003, 37:220\u2013225.","journal-title":"J Clin Gastroenterol"},{"key":"42_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1542-3565(05)00738-X","volume":"3","author":"S Matula","year":"2005","unstructured":"Matula S, Croog V, Itzkowitz S, et al.: Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005, 3:1015\u20131021.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"42_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/gast.2003.50014","volume":"124","author":"A Francella","year":"2003","unstructured":"Francella A, Dyan A, Bodian C, et al.: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9\u201317. This is an important retrospective cohort study supporting the continuation of 6-MP therapy in female IBD patients who are pregnant or contemplating pregnancy.","journal-title":"Gastroenterology"},{"key":"42_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00054725-200108000-00001","volume":"7","author":"MC Dubinsky","year":"2001","unstructured":"Dubinsky MC, Hassard PV, Seidman EG, et al.: An openlabel pilot study using thioguanine as a therapeutic alternative in Crohn\u2019s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001, 7:181\u2013189. This is a pilot study of the successful use of thioguanine in patients previously intolerant or unresponsive to AZA or 6-MP. Subsequent findings of hepatotoxicity have limited use of this agent.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0016-5085(03)00938-7","volume":"125","author":"MC Dubinsky","year":"2003","unstructured":"Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298\u2013303.","journal-title":"Gastroenterology"},{"key":"42_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0399-8320(05)80754-7","volume":"29","author":"L Message","year":"2005","unstructured":"Message L, Bourreille A, Laharie D, et al.: Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005, 29:231\u2013235.","journal-title":"Gastroenterol Clin Biol"},{"key":"42_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s003840100346","volume":"17","author":"P Rolny","year":"2002","unstructured":"Rolny P, Sadik R: Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy. Int J Colorectal Dis 2002, 17:67\u201369.","journal-title":"Int J Colorectal Dis"},{"key":"42_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","volume":"17","author":"S Campbell","year":"2005","unstructured":"Campbell S, Travis S, Jewell D: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005, 17:79\u201384.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"42_CR12","first-page":"65","volume":"95","author":"GC Actis","year":"2004","unstructured":"Actis GC, Lagget M, Rizzetto M, et al.: Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis [in Italian]. Minerva Med 2004, 95:65\u201370.","journal-title":"Minerva Med"},{"key":"42_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2036.2005.02552.x","volume":"22","author":"P de Saussure","year":"2005","unstructured":"de Saussure P, Soravia C, Morel P, Hadengue A: Lowdose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005, 22:203\u2013208.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/00054725-200209000-00002","volume":"8","author":"K Fellermann","year":"2002","unstructured":"Fellermann K, Tanko Z, Herrlinger KR, et al.: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002, 8:317\u2013324. This large study suggests equivalent efficacy between oral and intravenous dosing of tacrolimus in the treatment of refractory colitis.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-2036.2003.01662.x","volume":"18","author":"C Hogenauer","year":"2003","unstructured":"Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W: Effect of oral tacrolimus (FK 506) on steroid-refractory moderate\/severe ulcerative colitis. Aliment Pharmacol Ther 2003, 18:415\u2013423.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1572-0241.2000.02010.x","volume":"95","author":"T Orth","year":"2000","unstructured":"Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201\u20131207. This pilot study suggests that whereas mycophenolate was effective in some patients with refractory colitis, the efficacy and safety were worse than in patients receiving standard AZA therapy.","journal-title":"Am J Gastroenterol"},{"key":"42_CR17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1046\/j.1365-2036.2003.01581.x","volume":"17","author":"AC Ford","year":"2003","unstructured":"Ford AC, Towler RJ, Moayyedi P, et al.: Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17:1365\u20131369.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00054725-200203000-00004","volume":"8","author":"MM Skelly","year":"2002","unstructured":"Skelly MM, Logan RF, Jenkins D, et al.: Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:93\u201397.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2036.2005.02331.x","volume":"21","author":"JR Cummings","year":"2005","unstructured":"Cummings JR, Herrlinger KR, Travis SP, et al.: Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21:385\u2013389.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR20","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","volume":"95","author":"HS Te","year":"2000","unstructured":"Te HS, Schiano TD, Kuan SF, et al.: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150\u20133156. This prospective study showed that routine liver biopsy is not warranted in IBD patients receiving a cumulative dose of MTX greater than 1500 g without other risk factors or signs of liver disease.","journal-title":"Am J Gastroenterol"},{"key":"42_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00054725-200105000-00002","volume":"7","author":"GR Lichtenstein","year":"2001","unstructured":"Lichtenstein GR: Is infliximab effective for induction of remission in patients with ulcerative colitis?\n                           Inflamm Bowel Dis 2001, 7:89\u201393.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","volume":"7","author":"BE Sands","year":"2001","unstructured":"Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83\u201388.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/gut.52.7.998","volume":"52","author":"CS Probert","year":"2003","unstructured":"Probert CS, Hearing SD, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998\u20131002.","journal-title":"Gut"},{"key":"42_CR24","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462\u20132476. This is a combination of two large, randomized, placebocontrolled, multicenter, international trials establishing the efficacy of infliximab in the induction and maintenance of remission in patients with refractory UC.","journal-title":"N Engl J Med"},{"key":"42_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 2003, 348:601\u2013608. This analysis identifies that co-administration of AZA, 6-MP, or MTX results in lower rates and titers of anti-infliximab antibodies, fewer infusion reactions, and higher serum levels of infliximab.","journal-title":"N Engl J Med"},{"key":"42_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/gast.2003.50145","volume":"124","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology 2003, 124:917\u2013924. This randomized, placebo-controlled trial shows that the pre-administration of intravenous hydrocortisone (200 mg) before the initial infliximab infusion, and administration of a second infliximab infusion within 8 weeks of the first, results in lower levels of anti-infliximab antibodies and longer patient responses to therapy.","journal-title":"Gastroenterology"},{"key":"42_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/00004836-200208000-00007","volume":"35","author":"JH Rubenstein","year":"2002","unstructured":"Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn\u2019s disease. J Clin Gastroenterol 2002, 35:151\u2013156. This is the initial study demonstrating substantial decrease in the utilization of health care resources in Crohn\u2019s patients following initiation of infliximab therapy.","journal-title":"J Clin Gastroenterol"},{"key":"42_CR28","doi-asserted-by":"publisher","first-page":"A521","DOI":"10.1016\/S0016-5085(03)82636-7","volume":"124","author":"J Harrison","year":"2003","unstructured":"Harrison J, Rubenstein J, Leff A, Cohen R: A controlled trial of the impact of infliximab upon health care utilization, costs, and charges in patients with Crohn\u2019s disease [abstract]. Gastroenterology 2003, 124:A521.","journal-title":"Gastroenterology"},{"key":"42_CR29","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/00042737-200510000-00007","volume":"17","author":"DP Jewell","year":"2005","unstructured":"Jewell DP, Satsangi J, Lobo A, et al.: Infliximab use in Crohn\u2019s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005, 17:1047\u20131052.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"42_CR30","first-page":"229","volume":"238","author":"H Tulchinsky","year":"2003","unstructured":"Tulchinsky H, Hawley PR, Nicholls J: Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003, 238:229\u2013234.","journal-title":"Ann Surg"},{"key":"42_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1046\/j.1365-2168.1998.00689.x","volume":"85","author":"AP Meagher","year":"1998","unstructured":"Meagher AP, Farouk R, Dozois RR, et al.: J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998, 85:800\u2013803.","journal-title":"Br J Surg"},{"key":"42_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1385\/1-59259-311-9:157","volume-title":"Inflammatory Bowel Disease: Diagnosis and Therapeutics","author":"RD Hurst","year":"2003","unstructured":"Hurst RD: Surgical management of inflammatory bowel disease. In Inflammatory Bowel Disease: Diagnosis and Therapeutics. Edited by Cohen RD. Totowa, NJ: Humana Press; 2003:157\u2013199."},{"key":"42_CR33","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/S0016-5085(03)00171-9","volume":"124","author":"P Gionchetti","year":"2003","unstructured":"Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial. Gastroenterology 2003, 124:1202\u20131209. This randomized, double-blind, placebo-controlled trial showed that an initial bout of pouchitis can be prevented with prophylactic use of the probiotic cocktail VSL#3\u00ae immediately following surgery.","journal-title":"Gastroenterology"},{"key":"42_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/gast.2000.9370","volume":"119","author":"P Gionchetti","year":"2000","unstructured":"Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305\u2013309. The first convincing clinical trial establishing a role for probiotics in patients with IBD, this randomized, double-blind, placebo-controlled trial demonstrated that pouchitis relapse can be prevented with the use of VSL#3\u00ae.","journal-title":"Gastroenterology"},{"key":"42_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/bjs.1800810536","volume":"81","author":"AP Leong","year":"1994","unstructured":"Leong AP, Londono-Schimmer EE, Phillips RK: Life-table analysis of stomal complications following ileostomy. Br J Surg 1994, 81:727\u2013729.","journal-title":"Br J Surg"},{"key":"42_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/00000658-198303000-00018","volume":"197","author":"JJ Bauer","year":"1983","unstructured":"Bauer JJ, Gelernt IM, Salky B, Kreel I: Sexual dysfunction following proctocolectomy for benign disease of the colon and rectum. Ann Surg 1983, 197:363\u2013367.","journal-title":"Ann Surg"},{"key":"42_CR37","doi-asserted-by":"publisher","first-page":"A","DOI":"10.1016\/S0016-5085(03)80033-1","volume":"124","author":"S Plevy","year":"2003","unstructured":"Plevy S, Salzberg B, Regueiro M, et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe, steroid-refractory ulcerative colitis: preliminary results of a phase I study [abstract]. Gastroenterology 2003, 124:A-7.","journal-title":"Gastroenterology"},{"key":"42_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","volume":"16","author":"FH Gordon","year":"2002","unstructured":"Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699\u2013705.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 2005, 353:362\u2013368.","journal-title":"N Engl J Med"},{"key":"42_CR40","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","volume":"352","author":"BG Feagan","year":"2005","unstructured":"Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499\u20132507.","journal-title":"N Engl J Med"},{"key":"42_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","volume":"16","author":"E Musch","year":"2002","unstructured":"Musch E, Andus T, Malek M: Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002, 16:1233\u20131239.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","volume":"3","author":"E Musch","year":"2005","unstructured":"Musch E, Andus T, Kruis W, et al.: Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005, 3:581\u2013586.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"42_CR43","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","volume":"52","author":"H Tilg","year":"2003","unstructured":"Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728\u20131733.","journal-title":"Gut"},{"key":"42_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1526-0968.2002.00441.x","volume":"6","author":"Y Kohgo","year":"2002","unstructured":"Kohgo Y, Hibi H, Chiba T, et al.: Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial. Ther Apher 2002, 6:255\u2013260.","journal-title":"Ther Apher"},{"key":"42_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/jcgh.2003.50005","volume":"1","author":"H Hanai","year":"2003","unstructured":"Hanai H, Watanabe F, Takeuchi K, et al.: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003, 1:28\u201335.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"42_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00054725-200405000-00012","volume":"10","author":"M Naganuma","year":"2004","unstructured":"Naganuma M, Funakoshi S, Sakuraba A, et al.: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251\u2013257.","journal-title":"Inflamm Bowel Dis"},{"key":"42_CR47","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.3748\/wjg.v11.i44.7001","volume":"11","author":"W Kruis","year":"2005","unstructured":"Kruis W, Dignass A, Steinhagen-Thiessen E, et al.: Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005, 11:7001\u20137006.","journal-title":"World J Gastroenterol"},{"key":"42_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1365-2036.2003.01639.x","volume":"18","author":"TJ Creed","year":"2003","unstructured":"Creed TJ, Norman MR, Probert CS, et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003, 18:65\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"42_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1572-0241.2003.07239.x","volume":"98","author":"G Van Assche","year":"2003","unstructured":"Van Assche G, Dalle I, Noman M, et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003, 98:369\u2013376.","journal-title":"Am J Gastroenterol"},{"key":"42_CR50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1046\/j.1365-2362.2003.01130.x","volume":"33","author":"P Vernia","year":"2003","unstructured":"Vernia P, Annese V, Bresci G, et al.: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003, 33:244\u2013248.","journal-title":"Eur J Clin Invest"},{"key":"42_CR51","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1056\/NEJMoa013136","volume":"349","author":"A Sinha","year":"2003","unstructured":"Sinha A, Nightingale J, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mildto-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350\u2013357.","journal-title":"N Engl J Med"},{"key":"42_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMe030075","volume":"349","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ: Epidermal growth factor for ulcerative colitis. N Engl J Med 2003, 349:395\u2013397.","journal-title":"N Engl J Med"},{"key":"42_CR53","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1172\/JCI10182","volume":"106","author":"G Borkow","year":"2000","unstructured":"Borkow G, Leng Q, Weisman Z, et al.: Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 2000, 106:1053\u20131060.","journal-title":"J Clin Invest"},{"key":"42_CR54","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1053\/j.gastro.2005.01.005","volume":"128","author":"RW Summers","year":"2005","unstructured":"Summers RW, Elliott DE, Urban JF, et al.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825\u2013832. This is a landmark randomized, placebo-controlled, pilot trial suggesting a potential therapeutic role for helminths in the treatment of UC.","journal-title":"Gastroenterology"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0042-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11938-006-0042-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0042-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0042-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:15:54Z","timestamp":1659093354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11938-006-0042-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1007\/s11938-006-0042-3","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}